tiprankstipranks
Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
India Market
Want to see IN:GLENMARK full AI Analyst Report?

Glenmark Pharmaceuticals Limited (GLENMARK) Stock Forecast & Price Target

5 Followers
See the Price Targets and Ratings of:

GLENMARK Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Glenmark
Pharmaceuticals Limited
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GLENMARK Stock 12 Month Forecast

There Are No Analyst Ratings for IN:GLENMARK In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

GLENMARK Financial Forecast

GLENMARK Earnings Forecast

Next quarter’s earnings estimate for GLENMARK is ₹18.20 with a range of ₹18.20 to ₹18.20. The previous quarter’s EPS was ₹14.28. GLENMARK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GLENMARK has Performed in-line its overall industry.
Next quarter’s earnings estimate for GLENMARK is ₹18.20 with a range of ₹18.20 to ₹18.20. The previous quarter’s EPS was ₹14.28. GLENMARK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GLENMARK has Performed in-line its overall industry.

GLENMARK Sales Forecast

Next quarter’s sales forecast for GLENMARK is ₹38.13B with a range of ₹37.17B to ₹39.25B. The previous quarter’s sales results were ₹39.01B. GLENMARK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GLENMARK has Performed in-line its overall industry.
Next quarter’s sales forecast for GLENMARK is ₹38.13B with a range of ₹37.17B to ₹39.25B. The previous quarter’s sales results were ₹39.01B. GLENMARK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GLENMARK has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
ICICI Securities Analyst forecast on IN:GLENMARK
ICICI Securities
ICICI Securities
₹1,640
Sell
-20.62%
Downside
Reiterated
02/03/26
ICICI Securities Sticks to Their Sell Rating for Glenmark Pharmaceuticals Limited (GLENMARK)
Motilal Oswal Analyst forecast on IN:GLENMARK
Unknown Analyst
Motilal Oswal
Not Ranked
Motilal Oswal
₹2,240
Buy
8.42%
Upside
Reiterated
02/02/26
Motilal Oswal Remains a Buy on Glenmark Pharmaceuticals Limited (GLENMARK)
HSBC
₹2,380₹2,370
Buy
14.72%
Upside
Reiterated
10/14/25
HSBC Keeps Their Buy Rating on Glenmark Pharmaceuticals Limited (GLENMARK)
Nomura
₹1,500
Hold
-27.39%
Downside
Reiterated
09/26/25
Nomura Sticks to Its Hold Rating for Glenmark Pharmaceuticals Limited (GLENMARK)
Investec
₹1,815₹2,510
Buy
21.49%
Upside
Reiterated
07/25/25
Investec Sticks to Their Buy Rating for Glenmark Pharmaceuticals Limited (GLENMARK)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
ICICI Securities Analyst forecast on IN:GLENMARK
ICICI Securities
ICICI Securities
₹1,640
Sell
-20.62%
Downside
Reiterated
02/03/26
ICICI Securities Sticks to Their Sell Rating for Glenmark Pharmaceuticals Limited (GLENMARK)
Motilal Oswal Analyst forecast on IN:GLENMARK
Unknown Analyst
Motilal Oswal
Not Ranked
Motilal Oswal
₹2,240
Buy
8.42%
Upside
Reiterated
02/02/26
Motilal Oswal Remains a Buy on Glenmark Pharmaceuticals Limited (GLENMARK)
HSBC
₹2,380₹2,370
Buy
14.72%
Upside
Reiterated
10/14/25
HSBC Keeps Their Buy Rating on Glenmark Pharmaceuticals Limited (GLENMARK)
Nomura
₹1,500
Hold
-27.39%
Downside
Reiterated
09/26/25
Nomura Sticks to Its Hold Rating for Glenmark Pharmaceuticals Limited (GLENMARK)
Investec
₹1,815₹2,510
Buy
21.49%
Upside
Reiterated
07/25/25
Investec Sticks to Their Buy Rating for Glenmark Pharmaceuticals Limited (GLENMARK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Glenmark Pharmaceuticals Limited

3 Months
Success Rate
5/5 ratings generated profit
100%
Average Return
+12.78%
Copying Damayanti Kerai's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +12.78% per trade.
1 Year
Success Rate
5/5 ratings generated profit
100%
Average Return
+34.88%
Copying Damayanti Kerai's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +34.88% per trade.
2 Years
Success Rate
5/5 ratings generated profit
100%
Average Return
+36.92%
Copying Damayanti Kerai's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +36.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GLENMARK Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
0
1
1
1
0
Hold
0
0
0
0
0
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
0
2
2
2
0
In the current month, GLENMARK has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GLENMARK average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

GLENMARK Stock Forecast FAQ

What is IN:GLENMARK’s average 12-month price target, according to analysts?
Currently, no data Available
What is IN:GLENMARK’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for IN:GLENMARK, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Glenmark Pharmaceuticals Limited a Buy, Sell or Hold?
      Currently, no data Available
      What is Glenmark Pharmaceuticals Limited’s share price target?
      Currently, no data Available
      What do analysts say about Glenmark Pharmaceuticals Limited?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Glenmark Pharmaceuticals Limited?
      To buy shares of IN:GLENMARK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.